Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
Journal of Clinical Psychopharmacology|November 14, 2009
Onset and persistence of antipsychotic response in patients with schizophreniaIra D Glick, Cynthia A Bossie, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJohn M Kane, Michael Cohen, Jun Zhao, et al.
Schizophrenia Research|July 22, 2011
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneJennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 19, 2019
An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant DepressionCarmela Benson, Holly Szukis, John J Sheehan, et al.
Early Intervention in Psychiatry|September 26, 2015
Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvementLarry Alphs, Cynthia Bossie, Lian Mao, et al.
Psychiatry Research|August 12, 2009
Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophreniaDawn I Velligan, Larry Alphs, Scott Lancaster, et al.
Schizophrenia Research|June 12, 2017
Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE studyH Lynn Starr, Jason Bermak, Lian Mao, et al.
Neuropsychiatric Disease and Treatment|January 27, 2021
The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National SurveyCarmela Benson, David Singer, Colleen M Carpinella, et al.
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief TrainingLarry Alphs, Robert Morlock, Cheryl Coon, et al.
BMC Psychiatry|October 8, 2013
Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalizationMichael Markowitz, Sudeep Karve, Jessica Panish, et al.
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
Journal of Clinical Psychopharmacology|November 14, 2009
Onset and persistence of antipsychotic response in patients with schizophreniaIra D Glick, Cynthia A Bossie, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJohn M Kane, Michael Cohen, Jun Zhao, et al.
Schizophrenia Research|July 22, 2011
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidoneJennifer Kern Sliwa, Cynthia A Bossie, Yi-Wen Ma, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 19, 2019
An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant DepressionCarmela Benson, Holly Szukis, John J Sheehan, et al.
Early Intervention in Psychiatry|September 26, 2015
Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvementLarry Alphs, Cynthia Bossie, Lian Mao, et al.
Psychiatry Research|August 12, 2009
Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophreniaDawn I Velligan, Larry Alphs, Scott Lancaster, et al.
Schizophrenia Research|June 12, 2017
Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE studyH Lynn Starr, Jason Bermak, Lian Mao, et al.
Neuropsychiatric Disease and Treatment|January 27, 2021
The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National SurveyCarmela Benson, David Singer, Colleen M Carpinella, et al.
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief TrainingLarry Alphs, Robert Morlock, Cheryl Coon, et al.
BMC Psychiatry|October 8, 2013
Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalizationMichael Markowitz, Sudeep Karve, Jessica Panish, et al.
Pageof 12